Prostate Cancer Archives

Oncotarget News

Using Early On-treatment Circulating Tumor DNA Measurements as Response Assessment in Metastatic Castration Resistant Prostate Cancer

July 17, 2024

results of Tolmeijer et al. show the promise of on-treatment ctDNA detection as early read out for treatment response to potentially help guide treatment management of patients with mCRPC.”BUFFALO,... read more

Oncotarget

Starving Cancer Cells to Enhance DNA Damage and Immunotherapy Response

June 26, 2024

Depleting amino acid[s] likely expose[s] the Achilles heel of the cancer and exacerbate[s] DNA repair-targeted and immune-based therapy response.”BUFFALO, NY- June 26, 2024 – A new research... read more

Figure 5: AI-generated PET results shown overlaid on CT.

Oncotarget

Deep Learning-based Whole-body Prostate-specific Membrane Antigen PET/CT Attenuation Correction

May 8, 2024

We have developed a Pix-2-Pix GAN model to perform attenuation correction on whole-body PSMA [prostate-specific membrane antigen] PET images with 18F-DCFPyL.”BUFFALO, NY- May 8, 2024 – A new research paper... read more

Figure 1: Optimization of circulating tumor cells (CTC) staining and validation of p300 activity.

Oncotarget

A Multiplex Assay to Assess Activated p300/CBP in Circulating Prostate Tumor Cells

July 24, 2023

The results from this initial cohort support the integration of these biomarkers into prospective clinical trials.”BUFFALO, NY- July 24, 2023 – A new research paper was published in Oncotarget's Volume... read more

Figure 4: Variable changes in phosphorylation of S6 kinase 1 was observed in both cohorts. metformin

Oncotarget

Metformin’s Role in Preventing Metabolic Syndrome during Androgen Deprivation Therapy: A Phase II Study

June 20, 2023

we found no impact of the addition of metformin to [androgen deprivation] therapy on risk of metabolic syndrome associated with castration therapy and no additional anti-tumor effects.”BUFFALO, NY- June... read more

Oncotarget

Oncotarget | Mitochondria Engage the Integrated Stress Response to Promote Tumor Growth

March 8, 2023

Overall, this research proposes a new paradigm on how AR-independent PCa can drive tumor traits by exploiting mitochondrial signaling pathways [...]” BUFFALO, NY- March 8, 2023 – A new editorial paper... read more

Oncotarget

Oncotarget | Unveiling the Non-canonical Functions of EZH2 in Prostate Cancer

March 3, 2023

In summary, both articles by Yi et al. emphasized the significance of non-canonical functions of EZH2 during PCa [prostate cancer] development [...]” BUFFALO, NY- March 3, 2023 – A new editorial... read more

Oncotarget

Behind the Study: Role of Cancer Associated Fibroblasts in Prostate Cancer

March 17, 2022

Dr. Nerymar Ortiz-Otero from the Meinig School of Biomedical Engineering, Cornell University, discusses a research paper she co-authored that was published by Oncotarget in Volume 11, Issue 12, entitled, “Cancer... read more

Oncotarget

Testimonial: Dr. Reshma Sundar and Dr. Marene Landström

November 12, 2021

Below is a transcript of testimonials by Dr. Reshma Sundar and Dr. Marene Landström from the Department of Medical Biosciences at Umeå University in Sweden on their... read more

Oncotarget

Behind the Study: Evaluations in TRAMP Prostate Cancer Model

September 20, 2021

Behind the Study is a series of transcribed videos from researchers elaborating on their oncology-focused studies published by Oncotarget. A new Behind the Study is released each Monday.... read more